Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company ...

This collection of health news showcases a range of significant developments: measles cases are surging in Texas and New ...

CRISPR technique can target single genes essential for cancer cell survival, toppling the whole structure, says nanomedicine ...